Lexaria Bioscience Corp. (NASDAQ: LEXX) stock gained by 0.74% at last close while the LEXX stock price rises by 10.11% in the pre-market trading session. DehydraTECH, a Lexaria Bioscience patented drug delivery system, enhances the way active medicinal ingredients (APIs) reach the bloodstream by encouraging healthier oral absorption approaches and increasing the efficacy of fat-soluble active molecules, resulting in reduced total dosing.
What is happening?
In its second 2021 applied research and innovation study program, HYPER-A21-2, LEXX is delighted to announce the promising test results of two new “DehydraTECHTM 2.0” cannabidiol formulations.
Three new DehydraTECH 2.0 formulation variants were used in the HYPER-A21-2 study to improve CBD distribution efficiency and pharmacokinetic optimization. As a comparison to Lexaria’s initial DehdyraTECH 1.0 and 2019 DehydraTECH 2.0 concentration-matched formulations, as well as a medium-chain triglyceride (“MCT”) oil-based control formulation indicative of current market standards, two of the three latest DehydraTECH 2.0 formulations performed better.
Lexaria continues to develop a strong body of evidence showing that its proprietary DehydraTECH technology can greatly improve the distribution of lipophilic active ingredients like CBD across a broad variety of uptake stages, with possible uses in consumer packaged products as well as medications with disease treatment potential.
Lexaria also states that dosing for its HYPER-H21-1 human clinical hypertension trial is virtually complete, with a formulation that is most similar to the initial 2019 DehydraTECH 2.0. These formulation improvements, along with a more than 3-fold rise in dose quantity, are anticipated to be more effective than the initial DehydraTECH 1.0 formulation used in Lexaria’s foundational 2018 human clinical study, which showed visible blood pressure reduction despite being published and available at PubMed. As a result, Lexaria anticipates that improved pharmacokinetic success in its latest human clinical trial would translate into improved pharmacodynamic performance. However, Lexaria will give details on the results of the study HYPER-H21-1 as soon as it becomes available.